Overview
Pulmonary nodules are frequently detected during diagnostic chest imaging and as a result of lung cancer screening. Current guidelines for their evaluation are largely based on low-quality evidence, and patients and clinicians could benefit from more research in this area. In this research statement from the American Thoracic Society, a multidisciplinary group of clinicians, researchers, and patient advocates reviewed available evidence for pulmonary nodule evaluation, characterized areas to direct future research efforts, and identified fundamental gaps in knowledge and strategies to address them.
We developed the following key recommendations:
Introduction
Hundreds of thousands of patients are diagnosed every year with incidental pulmonary nodules (1) (2) (3) , fueled by the everincreasing number of individuals who undergo imaging studies (4) (5) (6) (7) . The number of patients with pulmonary nodules will increase, because multiple organizations, including the American Thoracic Society (ATS), recommend annual low-dose computed tomography (CT) screening for adults at high risk of developing lung cancer (8) (9) (10) (11) (12) (13) . These recommendations are based on the results of the National Lung Screening Trial, which showed that screening decreased lung cancer mortality (14) . But this benefit came with a substantial drawback, as almost 40% of subjects had a positive screening test result during the three rounds of screening, mostly as a result of pulmonary nodule identification.
The majority of pulmonary nodules are benign, but the most worrisome cause of a pulmonary nodule is bronchogenic carcinoma. Because of the lethality of lung cancer, the difficulty of sampling small lesions for biopsy, and the relatively slow rate of growth even if the nodule is lung cancer, it is recommended that most patients with nodules undergo further evaluation (15) (16) (17) . Patients essentially have three options to consider after a nodule is identified: (1) active surveillance; (2) additional diagnostic procedures, including positron emission tomography (PET), biopsy (percutaneous or bronchoscopic), and surgical removal; or (3) no further monitoring or workup (17, 18) . Optimizing benefit and reducing risk for patients undergoing nodule evaluation requires the patient and clinician to balance a desire for the certainty of a diagnosis against the tolerance for the unknown, while assessing the likelihood of malignancy, the yield and risk of invasive procedures, and the potential risk of delayed diagnosis and treatment of cancer. Patients with pulmonary nodules want to know how likely the nodule is to be cancer, what are the safest and most reliable methods of diagnosis, which nodules can be serially observed and which need more invasive evaluation, and what are the best ways to discuss these concerns with their clinicians (19, 20) . For the most part, answers to these fundamental questions are based on limited, indirect, or low-quality evidence.
We convened a workshop to establish a framework for lung nodule evaluation research and to facilitate the pace, impact, and efficiency of discovery. Outlining important research questions and potential strategies for evaluation by multidisciplinary groups can better and more effectively address the needs of patients (21) .
Methods
We assembled an international multidisciplinary (medical oncology, nursing, pulmonary, radiology, thoracic surgery, and public health) group of researchers, clinicians, and patient advocate stakeholders with expertise in pulmonary nodules at the May 2013 ATS International Conference. We The chairs (C.G.S. and M.K.G.) identified several topics for discussion that were vetted before the workshop. Participants were selected as moderators for breakout sessions, and each provided input about the planned agenda. We selected six focus areas: (1) diagnostic imaging and invasive procedures, (2) biomarkers, (3) prognostic models, (4) emerging treatments, (5) logistics and implementation, and (6) patient-centered outcomes.
The workshop consisted of presentations by experts in related fields, including screening for colorectal cancer, comparative effectiveness research, and lung cancer biomarker research. After these presentations, each participant engaged in breakout sessions in two of the focus areas, depending on interest. We did not use formal checklists or consensus methods, because we did not intend to prioritize one area or specific topic over another (21) .
If available, participants considered the findings of systematic reviews when evaluating these topics but did not conduct new or updated reviews. Participants discussed key questions related to five topics: (1) identify the information/knowledge gaps, (2) identify why the topic is important, (3) identify relevant stakeholders, (4) review appropriate methods and approaches to address the gaps, and (5) identify potential sources of research funding.
Participants also suggested potential derivatives. For example, we identified tools or methods that would enhance or facilitate research efforts. Participants also identified potential products that could be developed after evaluating many of the key questions. Each item includes: (1) a description, (2) how it would improve care or advance the field, (3) what resources would be required for development, (4) what resources would be required for validation and evaluation, and (5) how would it be implemented.
After the workshop, a writing committee drafted a report based on an AMERICAN THORACIC SOCIETY DOCUMENTS outline developed by the project co-chairs. The draft was circulated to the members of the writing group with revisions at each step and consensus achieved through discussion. The final document was approved by the ATS Board of Directors as an Official ATS Policy Statement.
The primary audience for this report includes clinicians, scientists, and patients who are affected by pulmonary nodules or lung cancer and undergo lung cancer screening. Institutions and organizations that solicit and fund research projects in these areas may also use this report to guide their efforts and decisions, particularly those that focus on patient-centered outcomes. Finally, healthcare systems and purchasers may find this report helpful when evaluating the evidence base for implementation of performance measures for the care of patients with pulmonary nodules.
Results
We identified several key questions and derivatives (Tables 1 and 2 ) for each focus area as well as several themes that overlapped multiple areas. These crosscutting themes are discussed first, followed by a section for each focus area.
Framing Research Questions for Novel Diagnostic Procedures
There is a fair amount of evidence that novel diagnostic imaging and invasive procedures, biomarkers, and predictive models can improve diagnostic accuracy and predict the risk of future events, such as developing lung cancer. Unfortunately, the evaluation of most of these tests and algorithms has been limited to uncontrolled studies of diagnostic accuracy performed in specialized centers. There are limited data regarding whether they influence outcomes that are more important to patients, clinicians, and/or healthcare systems. We agreed that novel diagnostic procedures should be proven to provide incremental value above and beyond currently available information before they are widely adopted into clinical care.
Many novel diagnostic tests and procedures have promise for improving care for patients with pulmonary nodules. These include imaging methodologies, such as computer-aided detection (X-ray [22] and CT scan [23] [24] [25] ), computer-aided diagnosis (CAD) (26) (27) (28) (29) , volume and mass analysis (30, 31) , gated PET imaging (32, 33) , PET imaging using novel radioactive tracers (32, 33) , novel algorithms to reconstruct CT images allowing lower radiation dose (32-34) (e.g., model-based iterative reconstruction), and procedures such as navigational bronchoscopy and radial ultrasound (17) . There is also great potential for novel biomarkers to distinguish benign from malignant nodules and aggressive versus relatively indolent cancers (35, 36) . Biomarkers can be classified in multiple ways based on anatomic site of sampling (e.g., serum, sputum, urine, and exhaled breath markers), target of detection (e.g., DNA methylation, gene expression, and ELISA), or type (e.g., DNA, microRNA, and autoantibody). In addition, several models using patient and nodule characteristics for predicting cancer risk in patients with solid nodules have been developed (37) (38) (39) (40) (41) , but more studies are needed to determine whether these models provide incremental value above and beyond clinical judgment and intuition (42) .
It is critical to develop novel diagnostic tests and strategies to improve diagnostic accuracy for patients with pulmonary nodules. But at least over the short term, it might be more impactful to demonstrate that existing diagnostic technologies improve patient-centered outcomes. Use of defined phases of research should guide how these tests are evaluated (43) (44) (45) (46) (Figure 1 ). Few to no prospective trials of diagnosis or the impact of potential novel tests or strategies on clinical outcomes have been performed.
It is important to consider which tests show the most promise to impact clinical practice when choosing candidates for prospective studies. Currently, most patients with nodules undergo follow-up CT scans (16) . Given the relatively low risk of serial imaging, the negative predictive value of a novel test will likely need to be very high to substantially reduce the number of patients who require follow-up imaging or the total number of scans these patients receive. Conversely, a novel test would need to have very high positive predictive value to recommend surgical resection when information from currently available imaging studies suggests the nodule is benign or can be safely monitored. Accordingly, studies that report the likelihood of how the biomarker would change decision-making (e.g., the net reclassification index [47] ) may be useful to guide decisions for which tests should be studied past Phase 2 ( Figure 1 ). In addition, explicit information of the risks of the novel test (including invasiveness and costs to patients and systems), feasibility, and data regarding the potential use of the test (see Reference 48 as an example) would strengthen research proposals.
Although developed for biomarkers, use of the prospective-specimen-collection and retrospective-blinded-evaluation (PRoBE) design may improve the rigor of intermediate phases of novel test development and could strengthen research proposals for other diagnostic tests and strategies (45) . The crux of the PRoBE design requires a priori consideration of how the novel test will change diagnostic accuracy above current methods while also stipulating data collection processes. Furthermore, while awaiting trials for evidence regarding the impact of diagnostic imaging and procedures on health outcomes, it may be helpful to use evidence-based grading systems to more formally evaluate their clinical utility (49, 50) .
Nodule Registries
The pace of discovery would be substantially improved through the creation of nodule registries. Current research is stymied by the lack of reliable methods to identify patients with nodules in routine practice. Notably, the ATS and American College of Chest Physicians recommend the use of a registry to support lung cancer screening efforts, and use of a registry is required by the Centers for Medicare and Medicaid Services (51, 52) . Registries should be based on protocolized radiology reports, with detailed information regarding imaging and nodule characteristics and recommendations (53) . As an example, the Lung Imaging Reporting and Data System (Lung-RADS), developed by the American College of Radiology to support lung cancer screening, is a reporting tool (54, 55) that could serve as one element of a registry. Ideally, data regarding risks for lung cancer and nodule development, such as age, smoking characteristics, occupational exposures (e.g., asbestos), family history, and geographic information (e.g., residence in endemic fungal areas and radon exposure) would be linked with the electronic medical record. Natural language processing is increasingly used to identify nodule characteristics and may be useful to identify other data from the electronic medical record that are not routinely collected in individual data fields (56) .
Registries should incorporate data regarding oncologic outcomes, procedures 
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(including complications), smoking cessation efforts, adherence to management guidelines, and resource use. The Surveillance, Epidemiology, and End Results (SEER)-Medicare Program (57) collects similar information and should guide the collection of patient-level variables. Healthcare systems may want to emulate the registry used by the Department of Veterans Affairs to support its pilot lung cancer screening program (58) . Some data may be challenging to collect by individual systems because patients frequently receive care at multiple institutions, so processes will need to be developed to link nodule data via healthcare information exchange. Registries should ideally be a core component of system-level interventions to facilitate patient care. They are unlikely to gain traction if solely used for research purposes. They should optimize current practices and information technology systems to be feasible, user friendly, and cost effective. Registries could be used to track patients to improve adherence to follow-up plans and longitudinally follow changes in nodule characteristics. Given that most institutions lack systematic methods to identify or follow patients with nodules, registries could guide quality-improvement efforts. They could also be used as recruitment tools for trials and in comparative effectiveness research (59) . Finally, registries themselves should be evaluated for their impact on patient-centered outcomes, healthcare system resource use, and costs.
Data Sharing
Registries are necessary but not sufficient to improve research efforts. Methods to share the data in registries are also required. For example, nodule consortiums could facilitate validation of prognostic models and increase the ability to test their clinical effectiveness. In addition, consortiums to pool clinical data with specimens should be developed. The ability to compare different diagnostic tests and implementation strategies will also be greatly facilitated by consortiums.
In particular, biomarker studies are often limited by lack of generalizability and inability to validate the marker in other settings. Registries should collect data regarding small sample acquisition and processing and have the ability to be linked with specimen banks. Several existing groups and consortiums could serve as models for collaboration, including COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT), the Early Detection Research Network of the National Cancer Institute, and the American College of Chest Physicians Quality Improvement Registry (AQuIRE) (60) (61-63).
Diagnostic Imaging and Invasive Procedures
Practice guidelines for the evaluation of lung nodules must be studied. Current recommendations regarding follow-up imaging and procedures after nodule detection (15) (16) (17) are based on indirect evidence regarding the risk of malignancy, the expected growth rate of malignant nodules, the capability to detect growth, and the risks of radiation, rather than evidence from randomized trials or large, well-designed observational studies. Guidelines for the management of subsolid nodules are grounded in even weaker evidence than those for solid nodules and should also be studied (15) . It may also be helpful for guideline developers to use a living guideline model to more rapidly and efficiently disseminate important developments in the field (64).
Biomarkers
Given expected changes in treatment options, it will be important to obtain adequate samples from small specimens. Although most developmental work to date has used specimens from patients with advanced lung cancer, more research is required to understand the accuracy and prognostic value of biomarkers in local and regional stage disease. Optimizing the ability to test for multiple markers in small samples will also help to evaluate pathogenesis of cancer development, growth, and spread. Focusing biomarker studies on mechanistic factors will facilitate development of targeted therapies that can decrease or stop malignant nodule growth and metastasis.
Prediction and Prognostic Models
It is important to determine what factors accurately estimate the probability of lung cancer among patients with nodules and whether their use leads to improved outcomes. Several models for predicting cancer risk in patients with solid nodules have been developed, but they require additional validation (37) (38) (39) (40) (41) . Only one model has explicitly included identification of multiple nodules as a predictor (39) . No model has been developed for subsolid nodules, a common finding among subjects undergoing lung cancer screening. It is also important to assess the value of incorporating into future models readily available CT scan findings, such as the presence of emphysema. Another key issue is related to the concern for overdiagnosis of screening-detected nodules. Models that accurately predict nodule growth, invasion, and metastasis or other determinants of prognosis would be valuable to clinicians and patients and may help reduce overtreatment of slow-growing cancers. Finally, it will be Figure 1 . Proposed phases of study designs for new diagnostic strategies for improving ability to predict which pulmonary nodules are benign and which are cancerous (adapted by permission from Reference 44).
Phases of study designs for new diagnostic strategies
Preclinical
Promising directions identified
AMERICAN THORACIC SOCIETY DOCUMENTS
useful to follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) reporting guidelines (65, 66) .
Emerging Treatments
Treatment options for early-stage lung cancer directly impact the evaluation of pulmonary nodules (17, 18) and thus should be rigorously evaluated. For instance, stereotactic body radiotherapy (SBRT) has rapidly disseminated as a treatment for patients with stage I nonsmall cell lung cancer at high risk for perioperative morbidity and mortality. A variety of other ablative therapies, such as radiofrequency ablation (RFA), cryoablation, and microwave ablation, have been used for inoperable patients (67) . However, there are no randomized trials comparing ablative therapies to surgery (67) , and recent studies of SBRT versus sublobar resection were terminated early due to poor accrual (68) . Because of the risks and challenges of biopsy in marginal surgical candidates, many patients with nodules undergo ablative therapy without a diagnosis of lung cancer (69) . It will be important to compare the efficacy and effectiveness of emerging therapies to surgery to guide decision-making about the risks and benefits of different evaluation strategies and treating patients with pulmonary nodules that may not be cancerous. Guidelines (17) and decision models (70) should be evaluated for which patients SBRT constitutes acceptable treatment when a tissue diagnosis is not established.
It is also important to study the effectiveness of novel therapies on cancer prevention and tumor growth among patients with nodules. Trials of novel prevention agents and comparative effectiveness studies of potential existing therapies (e.g., oral or inhaled iloprost) should be conducted (71) . Nodule growth on surveillance imaging may be an important intermediate outcome in these trials if they are underpowered to detect differences in lung cancer mortality (72) .
Logistics and Implementation
Processes for nodule evaluation should be optimally implemented into routine care settings, because many patients do not receive guideline-adherent follow up (73, 74) . Evidence supporting specific system-level interventions for nodule evaluation is limited, but these have been shown to be helpful in other settings (75) (76) (77) . Possible interventions could include: creation of multidisciplinary teams, standardized reporting of results, development of care pathways, and development of registries to track patients with nodules. It is important to study the facilitators and barriers, effects on health outcomes, unintended consequences, and cost effectiveness of these interventions.
Performance measures and quality metrics will undoubtedly be developed. Indeed, the dissemination of lung cancer screening into practice has been accompanied by calls to institute these measures (51, 78) . However, there is little high-quality evidence on which to base specific measures or to establish quality thresholds. A multistakeholder group should identify potential metrics, categorize the evidence base for their use, and suggest steps for adoption and implementation. Possible quality indicators include accuracy of image acquisition and processing, timeliness of reporting, the use of a tracking system, the percentage of benign diagnoses among surgically resected nodules, the percentage of nondiagnostic bronchoscopic and CT-guided nodule biopsies, timely diagnosis and treatment of malignant nodules, and complication rates from biopsies and resections. The ATS has previously recommended that measures be subjected to rigorous review and testing before widespread implementation (79) . In addition, it will be important to study the implementation process itself to more effectively and efficiently establish the interventions in real-world settings.
Patient-centered Outcomes
Patient centeredness is defined by the Institute of Medicine as care "that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions" (80) . To conduct innovative patient-centered research, the field should incorporate feedback from diverse stakeholders to understand the unmet needs of patients, their families, and their clinicians. Some patients suffer psychological harm when a pulmonary nodule is discovered during screening (81) (82) (83) (84) (85) or incidentally (19, 20, 86, 87) . We identified communication processes as the most likely factors that that could be modified to improve patient-centered outcomes. Tools and systems designed to improve communication processes should be evaluated regarding their effect on outcomes important to patients. To ensure these tools are helpful and ultimately used in practice, they should be developed with systematic input from stakeholders.
As a next step to this statement, it would be optimal to form an organized, multi-stakeholder group, similar to the CONCERT effort (88) . Like CONCERT, this effort should use formal consensus processes to elicit concerns and unmet needs from multiple stakeholders. The purpose of the group would be to prioritize research and assess the evolving needs of the patient and research community.
Discussion
Our workshop identified many research questions regarding the evaluation of pulmonary nodules. Given the large numbers of patients affected, which is likely to increase with the implementation of lung cancer screening, it is critical to conduct research to answer the most pressing questions.
We developed the following key recommendations: There were substantial overlaps in the key research gaps we identified. For instance, participants recognized the need to validate novel prediction models, imaging tests, invasive procedures, and biomarkers. We also agreed that these interventions need to be rigorously evaluated in randomized and/or pragmatic trials for their effects on patient, clinician, and healthcare system outcomes before widespread AMERICAN THORACIC SOCIETY DOCUMENTS implementation. The ATS may want to consider how to frame these issues more broadly, because processes related to the evaluation of diagnostic tests and prognostic markers are relevant to many problems in pulmonary, critical care, and sleep medicine. This framework would provide actionable criteria for discovery and validation and to assess impact on patient outcomes.
Pulmonary nodules are just one of many incidental findings commonly identified when patients undergo imaging procedures. A recent Presidential Commission for the Study of Bioethical Issues related to incidental and secondary findings recommended that professional organizations develop guidelines and best management practices; that research efforts should be funded to evaluate the frequency of incidental findings along with their costs, benefits, and harms; and that all affected patients have access to information regarding individualized risks and benefits to make informed decisions (89) . Researchers may want to use our framework along with this statement to guide future proposals.
Workshop participants identified the lack of nodule registries as a key barrier to research and quality improvement efforts. The American College of Radiology created the Breast Imaging Reporting and Data System (BI-RADS) to address a similar barrier (90) and could serve as a guide for nodule registries. This system was developed with input from multiple stakeholders, initially to support the needs of clinicians to better understand and use the information contained in radiology reports. We agreed that nodule registries need to be carefully designed and implemented and shown to be useful if they are to be widely adopted.
Limitations
We did not use formal methods to achieve consensus and therefore did not attempt to set priorities. We did not include representatives from health systems, purchasers, or groups that fund research, so inclusion of these stakeholders in future discussions may be helpful. The international participants did not seem to have disparate views, but this report likely does not fully represent the views of stakeholders from other countries. Finally, we included stakeholders from organizations that represent patients who are often identified with a nodule and influenced by lung cancer screening efforts, but there are no readily identifiable organizations that advocate specifically on behalf of patients with pulmonary nodules. We hope that one outcome of this statement is to facilitate the creation of multidisciplinary stakeholder groups that more fully incorporate patient views.
Conclusions
This statement establishes a research framework to address fundamental questions about the care of patients with pulmonary nodules. We engaged clinical and patient stakeholders to address questions of importance. This statement may help researchers develop impactful and innovative proposals and enable funders to better judge novel research proposals. We hope that it will quicken the pace and increase the efficiency of discovery to improve the quality of care for patients with pulmonary nodules. n
